Navigation Links
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
Date:5/15/2009

Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations

SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc. today announced that data from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2009 in Orlando, Florida. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors and is currently enrolling patients in an accelerated approval study in relapsed/refractory multiple myeloma and Phase 2 clinical studies in relapsed multiple myeloma and other malignancies.

Of note, results from Proteolix's Phase 2 study of carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma will be presented on Monday, June 1 during an oral session by Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York. The Phase 2 trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. In addition, results from a Phase Ib/II study of carfilzomib in patients with selected advanced metastatic solid tumors will be presented on Saturday, May 30 during an oral session by Peter Rosen, M.D., Medical Director, Tower Cancer Research Foundation and Emeritus Professor, UCLA.

A complete list of the company's oral and poster presentations at ASCO follows:

    Oral Presentations
      Saturday, May 30, 2009 at 5:00 p.m. ET
      Track: Developmental Therapeutics
      Session: Developmental Therapeutics: Molecular
'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
4. Proteolix Raises $79 Million in Series C Financing
5. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
8. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
9. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
10. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that the ... Russia , India and ... in 2013, roughly equal to the size of the ... BRIC market will experience much faster growth as a result of ... Other key findings from Decision Resources Group,s coverage of ...
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... JOSE, Calif. , Aug. 20, 2014 /PRNewswire-iReach/ ... highlights the transformative collaboration between the school,s bioengineering ... As part of the Intel® Software Academic Program, ... computer sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/20/2014)... NJ (PRWEB) August 20, 2014 WriteResult®, ... announced today that it has expanded its myPROpad™ ePRO ... the EQ-5D-5L, one of the most widely used ... measuring general health status. The EQ-5D is used during ... generate a measure that can be used to demonstrate ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2
... research center south of Madison, a group of scientists, ... about the ethical choices presented by biotechnology's expanding knowledge ... be the memory of Terri Schiavo. , ,Every day, ... patients such as Schiavo, the brain-damaged Florida woman who ...
... one person in a crowd who is proud to announce ... compulsive about reading the job classifieds. , ,Don't get me ... between the ubiquitous "excellent communication skills" and the ever popular ... every day, even if it happens to be my first ...
... maker of automotive and facility ... Pro-Tel Inc. for an undisclosed ... contracting company founded in 1961 ... employees. Its repair and maintenance ...
Cached Biology Technology:Schiavo's death calls attention to ethical issues weighed at Bioethics Forum 2Schiavo's death calls attention to ethical issues weighed at Bioethics Forum 3Is IT leadership a position or an attitude? 2Is IT leadership a position or an attitude? 3
(Date:8/21/2014)... pancreas digesting itself resulting in severe abdominal pain, vomiting ... 20,000 patients are diagnosed with the disease resulting in ... is restricted to intravenous fluid and nutritional support. ... Sciences, who led the research, said "The major causes ... and excessive alcohol intake combined with a high fat ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... ocean floor made by giant deep-sea single-celled organisms could ... animals, says biologist Mikhail "Misha" Matz from The University ... colleagues recently discovered the grape-sized protists and their complex ... is the first time a single-celled organism has been ...
... cofounded by Mauro Ferrari, Ph.D., of The University of ... the effectiveness of anti-cancer agents and other medications, has ... Texas Emerging Technology Fund (ETF). NMS was one ... were announced by Texas Gov. Rick Perry on Tuesday, ...
... body,s immune system hates strangers. When its security patrol ... is the problem when people with type 1 diabetes ... a donor pancreas produce robust amounts of insulin for ... However, the immune system tries to kill the new ...
Cached Biology News:Discovery of giant roaming deep sea protist provides new perspective on animal evolution 2Discovery of giant roaming deep sea protist provides new perspective on animal evolution 3Texas invests record $3.5 million in startup cofounded by UT's Mauro Ferrari 2Researcher tricks immune system in diabetic mice 2
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... The PROTEAN II xi multi-cell is for ... with efficient cooling capabilities. The PROTEAN II xi ... length, comb, type of glass plates, and cooling ... be converted to the PROTEAN II XL multi-cell ...
... The PROTEAN II xi cell, 16 cm, ... nucleic acids and proteins in agarose gels. The ... unit includes a central cooling core with gaskets, ... of glass plates, 4 sandwich clamps, upper buffer ...
Biology Products: